)
)
)
Understanding Evolving Sufficiency, Enablement and Plausibility Standards in the Life Sciences
Patent forums across the globe, including the EPO following G 2/21, are actively reassessing how sufficiency of disclosure, plausibility and enablement standards should be applied in practice. Panellists in this session will review how courts and patent offices across different jurisdictions are refining their approaches to these three closely related doctrines, and explore how the latest legislative developments in this area are impacting how life science patents are prosecuted, defended and challenged.
- Review how G2/21 has impacted plausibility and sufficiency of disclosure standards in Europe.
- Discuss whether the UPC and national courts are diverging from the EPO’s assessment in G2/21.
- Learn how plausibility standards are diverging between the UK and the EU.
- Understand sufficiency, enablement and plausibility risks to life science patents, and how companies can adapt to reduce the risk of invalidation.
- Compare sufficiency and enablement standards between Europe, the U.S. and China, and discuss how the latest case law might impact litigation strategies.
